nice I was worry they don't have the balls to do it.
SNPMarketScopeResearchNotes2015-12-16 13:07:31.000VRXVALEANT PHARMACEUTICALS INTERNATIONAL, INC.Jeffrey Loo, CFAS&P CAPITAL IQ REITERATES BUY OPINION ON SHARES OF VALEANT PHARMACEUTICALSAt its analyst day, VRX updated Q4 15 and '16 sales and EPS guidance. VRX says it lost 20% of its scripts in Q4 due to the business disruption, mainly all from ending Philidor relationship. VRX now sees Q4 EPS of $2.55-$2.65, down from $4.00-$4.20 and sees 2016 sales of $12.5B-$12.7B and EPS of $13.25-$13.75. We lower our 2015 and 2016 EPS estimate $1.19 and $1.75 to $10.31 and $13.75. We keep our 12-month target at $155 based on 11.3X our 2016 EPS estimate, below peers on continued volatility and uncertainty. But we view recent events such as Walgreens deal very positively.|US;VRX|3254|CA|26796696
only stupid shorts are left, someone took advantage and cover during the rumors.